ChromaDex Corporation (CDXC) ニュース

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging...

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

ChromaDex to Participate in the 17th Annual LD Micro Main Event

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced...

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

This award recognizes Dr. Nkrumah-Elie’s dedication to advancing scientific excellence for ChromaDex’s leading...

Form 8-K - Current report

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today...

Form 8-K - Current report

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces...

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen...

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Commemorating a quarter of a century with an exclusive 25% off lifelong subscription on Tru Niagen® ChromaDex Corp. (NASDAQ:CDXC), the global...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced...